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Abstract 
Despite the widespread application of drug modelling in psychiatric research, the relative 
value of multiple models has never been formally compared in the same analysis. Here we 
compared the ability of 5 drugs (cannabis, psilocybin, amphetamine, ketamine and alcohol) to 
model psychiatric symptoms in a two-part subjective analysis. In the first part, mental health 
professionals associated statements referring to specific experiences, e.g. ‘I don’t bother to 
get out of bed’, to one or more psychiatric symptom clusters e.g. depression and negative 
psychotic symptoms. This measured the specificity of an experience for a particular disorder. 
In the second part, individuals with personal experience with each of the above-listed drugs 
were asked how reliably each drug produced the experiences listed in part 1, both acutely and 
sub-acutely. Part 1 failed to find any experiences that were specific for negative or cognitive 
psychotic symptoms over depression. The best model of positive symptoms was psilocybin 
and the best models overall were the acute alcohol and amphetamine models of mania. These 
results challenge current assumptions about the relative value of drug models and motivate 
further research on this understudied issue.  
 
Introduction 
Drug models of mental illness are useful in psychiatry as they help to inform hypotheses on 
the biology of pathological states and provide a valuable testing ground for novel 
medications. Psychosis has proved a popular domain for drug models. Psychotomimetics 
(psychosis-mimickers) that have received particular attention include: cannabis or delta-9-
tetrahydrocannabinol (THC) (Kalant, 1971), serotonergic psychedelics such as psilocybin and 
LSD (Hoch et al., 1952), amphetamines (Bell et al., 2009) and the dissociative anaesthetic 
agents phencyclidine (PCP) and ketamine (Luby et al., 1959, Johnson, 1971). However, few 
studies have compared the relative accuracy of drug models in a controlled manner 
(Gouzoulis-Mayfrank et al., 2005), and consequently, it is difficult to say which drug offers 
the most complete model of psychosis.  
 
It has been claimed that certain drugs can reliably produce spiritual-type experiences that are 
indistinguishable from spontaneously occurring spiritual experiences (Griffiths et al., 2006). 
However, clinicians sometime identify such phenomena as psychopathological (Moreira-
Almeida, 2012). Thus, this study also sought to address this matter by enquiring about: 1) the 
specificity of apparent spiritual experiences over psychopathological symptoms, and 2) the 
reliability with which such states can be induced by different drugs.   
 
A comparison of the relative strengths and weaknesses of different drug models of mental 
states is fraught with difficulty. For example, the same drug may induce different effects in 
different people (e.g. drug naïve research volunteers versus experienced drug users) and in 
different social contexts (e.g. in a clinical study versus at home). Two factors are especially 
important when evaluating a model of a disorder: 1) How closely the features of the model 
resemble the symptoms of a specific disorder, and 2) How often these features occur in the 
model. In the context of drug models of psychiatric disorders, an optimal model should 
reliably produce an experience that is typical of a specific disorder. This would effectively 
imply that the drug-induced and endogenous states are so similar and distinctive that strong 
inferences can be made about the endogenous state based on the induced state.  
 
It is a relatively simple task to determine the reliability with which a drug can produce an 
endogenous state. However, determining the degree to which a particular experience is 
uniquely or exclusively associated with a particular disorder or symptom cluster is slightly 
more complicated. For example, if the experience of finding it difficult to concentrate is 
common to a range of disorders, then a drug that makes it difficult for someone to 
concentrate will not be useful in making predictions about one disorder compared with 
another. As will be discussed below, the issue of the degree to which a drug model is 
uniquely associated with a given illness has been neglected in previous model evaluations. 
 
In this 2-part study, using novel methodologies, we sought to address an important and 
unanswered question: what are the best drug models of psychiatric illness? This subjective 
study was conceived as a pilot study to motivate and inform the design of a larger controlled 
study.    
 
Methods 
Basic design:  
To address the question of the relative merits of different drug models, we devised a 
subjective pilot study in 2 parts. In the first part, mental health professionals were contacted 
and asked to complete a web-based survey in which they were presented with a number of 
first-person statements and asked to rate how closely they resembled particular mental states 
or symptom clusters, namely: positive psychotic symptoms, negative psychotic symptoms, 
cognitive symptoms of psychosis, thought disorder, depression, anxiety, mania, and spiritual 
experiences.  
 
In the second part of the study, we devised a survey to be completed by drug users with 
personal experience with 5 different drugs: high potency cannabis, psilocybe magic 
mushrooms, ketamine, amphetamine and alcohol. Respondents were presented with a subset 
of the statements from part 1 and asked to say whether and how often they experienced the 
referred to phenomena, when under the acute influence of a drug, and in the subacute period 
following its use.  
 
This study received ethical approval from Imperial College Research Ethics Committee. The 
surveys for each part were built using the Bristol Online Surveys service 
(www.survey.bris.ac.uk) and can be found in the supplementary material. 
 
Participants: 
Part 1: 
A link to the part 1 survey was emailed to psychiatrists and clinical psychologists known to 
us who were asked to complete the survey. We also asked them to forward it onto eligible 
colleagues (to be eligible, respondents simply had to be mental health professionals). Sixty 
three mental health professionals completed the survey. Demographic data is presented in 
table 1.  
 
Part 2: 
Two hundred and twenty four experienced drug users completed the part 2 survey. The 
survey was advertised on the drug user forums: www.bluelight.ru and www.drugs-forum.org, 
as well as the website www.maps.org which is an organisation concerned with promoting 
clinical research with psychedelic drugs. Two hundred and twenty four individuals responded 
to the survey. Each was required to have taken alcohol, high potency cannabis, amphetamine, 
psilocybin-containing magic mushrooms and ketamine on at least one occasion. 
Demographic data is presented in table 1.  
 
Survey format and procedure: 
Part 1:  
In the part 1 survey, respondents (mental health professionals) were presented with 58 first-
person statements referring to experiences or symptoms a psychiatric patient might describe 
(e.g. ‘I feel sad’, ‘my thoughts stop as if they are blocked’ and ‘I get worried that other 
people are plotting against me’; see supplementary material to view all 58 statements). Seven 
additional statements were included that are characteristic of spiritual-type experiences - 
based on the available literature on its phenomenology (Stace, 1961, James, 1902). The 
statements themselves were generated by a consultant psychiatrist and psychosis specialist 
(JMS), based on his own training and experience with patients – in discussion with RCH and 
DJN. Respondents were instructed to ascribe each statement to up to 8 different disorders or 
symptom clusters: 1) mania, 2) anxiety, 3) depression, 4) positive psychotic symptoms, 5) 
negative psychotic symptoms, 6) cognitive symptoms of psychosis and 7) formal thought 
disorder. Respondents could also select: 8) spiritual experiences and 9) none of these. More 
than one of the 9 options could be selected for each of the 58 statements, for example: ‘I feel 
worried or frightened’ might be ascribed to anxiety and to positive psychotic symptoms. The 
schedule of statements was designed to cover experiences associated with a range of 
psychiatric disorders – plus the spiritual experience. 
 
Seventeen statements from part 1 were selected for inclusion in part 2 based on how 
exclusively they were associated with a particular symptom cluster, their clinical significance 
and their relevance to drug-induced states. The number of statements had to be reduced 
because of the length of time required to complete the part-2 survey.  
  
We calculated a statement’s degree of association with a particular mental state as the number 
of ascriptions to that state over the number of ascriptions to other symptom clusters. This was 
then expressed as a percentage. For example, for the statement: ‘I become more talkative’, 
which was most closely associated with mania, its degree of association was calculated by 
summing the number of ascriptions to mania (61) over the total number of ascriptions to any 
mental state (35) + 61. That is, 61/96 * 100 = 64%, or ‘I become more talkative’ had a 64% 
association with mania. The 17 first person statements that were selected for the part 2 survey 
are shown in figure 1. 
 
Part 2:  
For each statement, respondents were instructed to select (from options ‘rarely/never’, 
‘sometimes’ or ‘often/always’), the frequency with which they experienced the effect 
described by each statement after taking at least a moderate dosage of each drug. 
Respondents were asked to do this for both the acute drug effects – i.e. the immediate ‘high’ 
– and separately for the post-acute effects – i.e. the comedown or withdrawal period. The 
following doses were provided as guidance of what was meant by a ‘moderate’ dose: 
Cannabis: at least one well loaded spliff/joint, deeply inhaled and shared between no more 
than two people, or at least one 'bowl' in a bong or pipe shared by no more than two people; 
alcohol: >3 pints of medium to high strength beer or cider, or at least 3 large glasses of wine; 
psilocybe mushrooms: at least 12 fresh liberty cap magic mushrooms or at least 1g of 
psilocybe cubensis; amphetamine: at least 500mg snorted or bombed amphetamine; 
ketamine: over 60mg snorted. 
 
Data Analysis for the part 2 survey: 
We quantified a drug’s ability to induce a particular symptom cluster or mental state as the 
mean percentage of part 2 respondents selecting ‘always/often’ for statements associated with 
a particular symptom cluster. For example, 77% of respondents said that acute amphetamine 
always or often made them more talkative, 24% said it always/often made them less worried 
about spending money or doing dangerous things and 34% said it always/often makes their 
thoughts go so quickly others can’t keep up with them. Thus, acute amphetamine’s 
‘reliability’ to induce mania-related symptoms is (77+24+34)/3 or 45%. The results of the 
part 2 survey are shown in figure 2. 
 
Results 
Demographic data are presented in Tables 1.  
  
Table 1. Demographic data for the sample of 
respondents to both surveys: A total of 63 mental 
health professionals completed the part 1 survey and 
224 experienced drug users completed part 2 survey. In 
the part 1 survey, respondents could select more than 
one speciality. Most respondents were psychiatrists 
(87%) and the remainder were psychologists. Seventy 
six percent were British. Most of the respondents in 
part 2 were male (79%), 50% were American and 23% 
were British.  
 
Part 1: mental health workers 
Profession N % 
Psychiatrist 55 87 
Psychologist 8 13 
Speciality  
Depression 24 38 
Bipolar/mania 26 41 
Psychosis 30 48 
Anxiety 23 37 
Addiction 21 33 
Spirituality 6 10 
Country 
Britain 48 76 
Other in Europe 4 6 
United States 6 10 
Australia 3 5 
Other 2 3 
Part 2: drug users 
Sex n  % 
Male 178 79 
Female 46 21 
Nationality 
British 51 23 
Irish 3 1 
Other European 25 11 
American 113 50 
Australian 12 5 
Canadian 15 7 
Other 5 2 
Found survey on: 
bluelight.ru 124 55 
drugs-forum.com 30 13 
maps.org 57 25 
Other 13 6 
Part-1 results: 
Figure 1 displays each symptom cluster and the statements that had the greatest degree of 
association with  them. None of the statements had any significant unique association with  
negative psychotic symptoms or cognitive symptoms of psychosis. This was mainly due to a 
high co-association between 4 symptom clusters: depressive symptoms, thought disorder, 
negative psychotic symptoms and cognitive symptoms of psychosis. For example, the 
statement ‘I can’t concentrate on things’ had a unique association of only 28% for its most 
closely related symptom cluster, depression, because although 90% associated this statement 
with depression, respondents also associated it with mania (37%), anxiety (49%), thought 
disorder (30%), negative symptoms of psychosis (17%) and cognitive symptoms of psychosis 
(43%). Indeed, even if negative symptoms and cognitive symptoms were collapsed into one 
symptom cluster (on the basis that they all describe functional deficits), no new statements 
were identified that had specificity for this single symptom cluster.  
 
The statements relevant to mania were the most uniquely or exclusively associated (70% 
mean association). Excluding negative and cognitive symptoms, for which no statements 
were uniquely associated, the symptom cluster with the least uniquely associated statements 
was thought disorder, with a mean association of 38.5%.  
 
 Figure 1. Part 1 survey results: These charts display the 17 first person statements that were 
used in the part 2 survey. Each chart shows the statements belonging to a particular disorder 
or symptom cluster and their degree of association with that symptom cluster. The title of the 
y axis, ‘specificity’, is synonymous with ‘exclusivity’ or the closeness of the association.   
  
Part 2 results: 
Drug models of positive psychotic symptoms: 
The results of the part 2 survey are displayed in figure 2. The first notable result was that 
none of the classic drug models of psychosis produced positive psychotic symptoms with any 
reliability. The best model of positive symptoms was acute psilocybin; however, even this 
had a low reliability of just 13% (i.e. 13% of respondents reported often or always 
experiencing positive symptoms after psilocybin), suggesting that although it was the best 
drug model of positive symptoms, it is not an especially reliable model.  
 
Drug models of thought-disorder: 
The best drug model of thought disorder was acute ketamine (27% reliability). However, 
even ketamine’s association with this symptom cluster showed that it was not especially 
reliable. Acute and sub-acute alcohol had a relatively high association with thought-disorder 
at 22% and 18% respectively.  
 
Drug models of the spiritual experience: 
The best drug model of the spiritual experience was sub-acute psilocybin with 37% 
reliability, followed by acute ketamine (33%) and psilocybin (30%). Acute and sub-acute 
psilocybin (53% and 48% reliability respectively) were closely associated with the statement 
‘I feel a profound inner peace’. In part 1, this statement was the most exclusively associated 
with a ‘symptom cluster’ or mental state, with an association of 77% for the spiritual 
experience (fig 1).  
 
 
 
Drug models of mania: 
The best drug model of mania was acute alcohol (46% reliability), closely followed by acute 
amphetamine (45%). The reliability with which acute alcohol and ketamine could produce 
manic symptoms was the highest of all of the drug-symptom associations.    
 
Drug models of depression:  
The 2 drugs that reliably produced manic symptoms when taken acutely were also those that 
most reliably produced depressive symptoms sub-acutely. Sub-acute alcohol and ketamine’s 
degree of association with depression was 24% and  25% respectively.  
 
Drug models of general anxiety: 
None of the 5 drugs produced symptoms of anxiety with any reliability. Acute cannabis 
(15%) and sub-acute amphetamine (15%) had the highest reliability to induce anxiety-related 
effects.  
  
 Figure 2. Part 2 survey results: Each chart represents a disorder or symptom cluster and the 
first-person statements associated with it, as determined by the results of the part 1 survey. 
The x-axis features the 5 different drugs enquired about in the survey, the acronym ‘SA’ is 
for ‘sub-acute’. The y-axis displays the percentage of respondents reporting that they ‘always 
or often’ have the relevant experience under the relevant drug. The black bar in each chart 
represents the mean of the different statements within the symptom cluster.   
 
 
 
Discussion 
A number of interesting findings emerged from this novel analysis. Firstly, none of the 4 
classic drug models of psychosis produced positive psychotic symptoms with any reliability. 
Psilocybin emerged as the best model of positive symptoms, which is consistent with the 
finding of a previous controlled study that compared the psychotomimetic properties of the 
psychedelic drug dimethyltryptamine with those of the dissociative ketamine (Gouzoulis-
Mayfrank et al., 2005). Nevertheless, only 13% of psilocybin users claimed to always or 
often experience positive psychotic symptoms after this drug. Indeed, drugs were less likely 
to produce positive psychotic symptoms than any of the other symptom clusters. This is in 
contrast to studies of acute administration of these drugs in a laboratory setting, in which 
positive psychotic symptoms are commonly reported (Krystal et al., 1994, Gouzoulis-
Mayfrank et al., 2005, Morrison et al., 2009).  
 
There are many possible reasons for this discrepancy. One is that the survey was completed 
by experienced drug users who may be more resilient to psychotomimetic effects than drug-
naïve healthy subjects. These individuals may be more reluctant to disclose adverse responses 
due to positively biased perspectives on these drugs, as well as ‘bravado’ - especially in the 
case of males (McLean and Anderson, 2009) who dominated the sample (80%). Furthermore, 
individuals who experience psychotic effects with these drugs may be less likely to take them 
recreationally and to frequent the websites on which this survey was advertised. It is also 
possible that the doses used in clinical studies have been higher, and the participants less 
experienced, or that clinical studies may be affected by implicit biases, especially where 
clinician administered scales are used. However, perhaps the most likely explanation for the 
discrepancy is that reactions to psychotomimetic drugs are known to be highly sensitive to 
the context in which they are taken. For example, the same drug, self-administered in a 
comfortable setting is less likely to elicit paranoid reactions than if it is administered by an 
unfamiliar person in an unfamiliar setting.  
 
A key question when evaluating a drug’s ability to model a multifarious condition like 
psychosis is: what specific aspect of the disorder is the drug supposed to be modelling? 
Auditory-verbal hallucinations are common in acute psychosis but very rare in drug states 
(Gouzoulis-Mayfrank et al., 1998), whereas anxious states engendering false inferences are 
much more common (Fletcher and Frith, 2009, Corlett et al., 2009, Mathys et al., 2011). This 
is supported by the sensitivity of psilocybin for the statement: ‘I think that things that I see 
and hear that I would not normally notice have been put there to give me a message’ (35% 
reported often/always experiencing this after psilocybin) which speaks to both the false 
inference (Fletcher and Frith, 2009) and aberrant salience (Kapur, 2003) models of psychosis. 
Auditory hallucinations can be thought of as transients in a mechanistic sense (Friston, 
1997), i.e. short-lived events occurring periodically. It may be that acute drug states are 
incapable of modelling such phenomena. It may be more realistic to consider only how a drug 
can model a specific acute state, and transients may be merely epiphenomena of prolonged 
states. We might speculate that there would be a greater likelihood of auditory hallucinations 
if a psychotomimetic drug was taken chronically – as repeated use might kindle emergent 
phenomena. This hypothesis is consistent with the psychotogenic potential of cannabis (Di 
Forti and Murray, 2005), for which there is a high prevalence of chronic use  (in contrast to 
psychedelic drugs, which are typically taken irregularly (Carhart-Harris and Nutt, 2010)). 
Fixed symptoms like auditory hallucinations may depend on a history - thus explaining why 
they are so difficult to model acutely.     
 
It is often claimed that the popular ketamine model of psychosis is superior to other drug 
models because it models both positive and negative symptoms of psychosis (Krystal et al., 
1994). However, some have questioned the construct validity of negative symptoms as they 
are not specific to schizophrenia (Sommers, 1985, Kaiser et al., 2011). Negative symptoms 
refer to such things as social withdrawal, emotional withdrawal, blunted affect and poverty of 
thought or speech. Statements included in the initial 58 that we thought might resonate with 
negative symptoms were: ‘I become emotionally withdrawn’, ‘I lose interest in doing things’, 
‘I don’t bother to get out of bed’, ‘I don’t want to socialise with other people’ and ‘I would 
rather not be around other people’. However, the mental health professionals who responded 
in the first survey were more likely to attribute these experiences to depression. 
Acknowledging that cognitive symptoms of psychosis might load onto the same factor as 
negative symptoms, we collapsed these into a single cluster to see if an improvement in 
specificity could be achieved – but still no statements could be identified that were unique to 
this new symptom cluster over depression.  
 
Importantly, these results do not imply that negative symptoms do not exist in schizophrenia, 
nor that they are seriously disabling; indeed, evidence suggest they are among the most 
prevalent and disabling symptoms (Ho et al., 1998). However, they do demonstrate that there 
is a great deal of overlap between self-reported negative and depressive symptoms and, from 
the present study, it is not possible to make any claims about the validity of currently 
proposed drug models of negative symptoms..  One possible reason why we were unable to 
identify any questions that were uniquely associated with negative symptoms in the present 
survey is that statements referring to blunted affect or to feelings of spontaneity were not 
included in part 1. It is possible that these statments may have been more likely to be 
associated with negative symptoms than depression by mental health professionals. 
 Perhaps the most surprising finding of the present study was the relative reliability with 
which acute alcohol produced symptoms of mania. Forty six percent of respondents said they 
often or always experienced manic symptoms after alcohol, and 45% said that they often or 
always experienced these after amphetamine. While amphetamine is an established drug 
model of mania (Mamelak, 1978), alcohol is not, and yet it produced symptoms with the 
highest exclusivity for any symptom cluster (70% specificity for mania). In comparing the 
alcohol versus amphetamine models of psychosis, it is interesting to note that alcohol was 
more associated with loss of inhibition about doing dangerous things, whereas amphetamine 
was associated with racing thoughts. It was also interesting that the best drug models of 
depression were sub-acute alcohol and amphetamine, with 24% of respondents reporting that 
they often or always experienced depressive symptoms during the alcohol hangover and 25% 
of respondents saying they experienced this during amphetamine withdrawal. Depression 
during amphetamine withdrawal has been documented before (Mamelak, 1978, Leith and 
Barrett, 1976, Seltzer and Tonge, 1975) as has depression post alcohol use (Sumnall et al., 
2004) and  acute and sub-acute amphetamine has been proposed as a model of bipolar 
disorder (Mamelak, 1978) but to our knowledge, the same has not been said of alcohol. 
Exaggerated mania has been described in manic patients presenting with concurrent alcohol 
misuse (Salloum et al., 2002) and so the relationship between alcohol use and bipolar 
disorder is worth investigating.   
  
A particularly novel feature of the present survey was its inclusion of first person statements 
relevant to the spiritual experience (Stace, 1961, Hood et al., 2009). This area is receiving 
growing interest after it was found that profound spiritual-type experiences could be reliably 
elicited in healthy volunteers after a single high dose of psilocybin (Griffiths et al., 2006). 
Moreover, these experiences tended to have a lasting impact, improving emotional wellbeing 
and increasing trait ‘openness’ over 12 months after the acute experience. These findings are 
consistent with the results of the present study since the best model of the spiritual experience 
was sub-acute psilocybin, with 39% of respondents saying that they often or always have 
spiritual-type experiences in the period following psilocybin use. Interestingly, the statement 
with the strongest association for any ‘symptom cluster’ was ‘I felt a profound inner peace’ 
(77% association with the spiritual experience). Over half of the respondents (53%) said they 
always or often experience this in the acute psilocybin state and 48% said they experience it 
in the sub-acute period following psilocybin. The unique association of statements for the 
spiritual experience over psychotic symptom clusters is telling as it suggests that the spiritual 
experience is non-pathological and distinct from psychosis (Moreira-Almeida, 2012). 
 
This study has some important limitations. Data was derived via web-based survey and 
although this is an efficient means of data collection that can open up unique possibilities, it 
is also requires the surrender of many experimental controls. We have no control over who 
completes the survey and no indication about the accuracy of their replies. Moreover, the 
respondents may have held biases, and this is a problem with subjective assessments in 
general. Also, respondents gave their assessments based on recreational use in naturalistic 
settings whereas controlled studies administer drugs in a very different context. That context 
can have such a marked influence on subjective responses to a drug is important; it implies 
that we should be cautious about making general inferences about a drug’s pharmacology 
based on a set of subjective reports – as a very different experiences may be produced by the 
same drug in a different context. Future research might try to assess drug by environment 
interactions in a controlled manner to better understand this phenomenon.  
 
Another possible criticism is that we could have collected more data. For example, we could 
have enquired about respondents’ ages and, in the case of part 2, the frequency of their drug 
use. However, the advantages of extending the surveys had to be balanced against the 
disadvantages of losing participants due to boredom or irritation with the length of the 
survey. 
 
In summary, the results of the present study suggest that the best drug models of psychiatric 
disorders are the acute alcohol and amphetamine models of mania, since these reliably 
produce symptoms that are relatively exclusive to a specific disorder. The results also suggest 
that drug models of positive psychotic symptoms are comparatively poor, at least when the 
drugs are taken naturalistically by experienced users. Psilocybin emerged as the best model of 
positive symptoms but models of negative symptoms could not be assessed because we failed 
to find any experiences that were specific for this symptom cluster over depression. Lastly, 
sub-acute psilocybin appeared to be a reliable model of non-pathological spiritual-type 
experiences – which may have implications for therapeutic applications of this drug (Griffiths 
et al., 2008, Grob et al., 2011).      
 
It is hoped that this pilot study will motivate a larger controlled study involving 
administration of a range of psychotomimetic drugs to healthy individuals. For example, in a 
within-subjects design, with sufficient time separating administrations, it would be interesting 
to compare the relative psychotomimetic properties of different drugs at different doses. It 
would also be interesting to incorporate rating scales for other disorders and symptom 
clusters (e.g. depression and specifically early psychotic symptoms) so that a drug’s 
psychotomimetic properties can be more accurately and specifically defined.   
 
To finish, it is hoped the present study has stimulated new thoughts about an understudied 
debate. Some of its implications challenge contemporary assumptions and therefore require 
follow-up by controlled research.  
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